These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 32212583)

  • 21. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
    Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
    Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei.
    Collett CF; Kitson C; Baker N; Steele-Stallard HB; Santrot MV; Hutchinson S; Horn D; Alsford S
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cutaneous leishmaniasis].
    Enk CD; Gardlo K; Hochberg M; Ingber A; Ruzicka T
    Hautarzt; 2003 Jun; 54(6):506-12. PubMed ID: 12759734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression analysis of activated protein kinase C gene (LACK1) in antimony sensitive and resistant Leishmania tropica clinical isolates using real-time RT-PCR.
    Hajjaran H; Kazemi-Rad E; Mohebali M; Oshaghi MA; Khadem-Erfan MB; Hajaliloo E; Reisi Nafchi H; Raoofian R
    Int J Dermatol; 2016 Sep; 55(9):1020-6. PubMed ID: 27336481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?
    Yardley V; Ortuno N; Llanos-Cuentas A; Chappuis F; Doncker SD; Ramirez L; Croft S; Arevalo J; Adaui V; Bermudez H; Decuypere S; Dujardin JC
    J Infect Dis; 2006 Oct; 194(8):1168-75. PubMed ID: 16991093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
    Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
    J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous leishmaniasis treatment.
    Minodier P; Parola P
    Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
    Escobar P; Yardley V; Croft SL
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Successful treatment of cutaneous leishmaniasis with amphotericin B; a case of unresponsive to pentavalent antimony therapy].
    Yeşilova Y; Turan E; Sürücü HA; Aksoy M; Özbilgin A
    Turkiye Parazitol Derg; 2015 Mar; 39(1):63-5. PubMed ID: 25917587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.
    Ephros M; Bitnun A; Shaked P; Waldman E; Zilberstein D
    Antimicrob Agents Chemother; 1999 Feb; 43(2):278-82. PubMed ID: 9925518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
    Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
    Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety].
    Saldanha AC; Romero GA; Merchan-Hamann E; Magalhães AV; Macedo Vde O
    Rev Soc Bras Med Trop; 1999; 32(4):383-7. PubMed ID: 10495667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
    Fernández OL; Diaz-Toro Y; Ovalle C; Valderrama L; Muvdi S; Rodríguez I; Gomez MA; Saravia NG
    PLoS Negl Trop Dis; 2014 May; 8(5):e2871. PubMed ID: 24853871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful Treatment of Disseminated Cutaneous Leishmaniasis With Liposomal Amphotericin B and Miltefosine in an Eight-year-old Girl.
    Hamzavi SS; Sanaei Dashti A; Kadivar MR; Pouladfar G; Pourabbas B
    Pediatr Infect Dis J; 2018 Mar; 37(3):275-277. PubMed ID: 29424815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp.
    Fernández O; Diaz-Toro Y; Valderrama L; Ovalle C; Valderrama M; Castillo H; Perez M; Saravia NG
    J Clin Microbiol; 2012 Jul; 50(7):2207-11. PubMed ID: 22518860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs.
    Jamal Q; Khan NH; Wahid S; Awan MM; Sutherland C; Shah A
    Exp Parasitol; 2015 Jul; 154():93-7. PubMed ID: 25911243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria.
    Eddaikra N; Ait-Oudhia K; Kherrachi I; Oury B; Moulti-Mati F; Benikhlef R; Harrat Z; Sereno D
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006310. PubMed ID: 29561842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
    Miret JA; Moreno J; Nieto J; Carter KC; Mullen AB; Ambros L; Rodríguez C; San Andrés MI; González F
    Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility to paromomycin in clinical isolates and reference strains of Leishmania species responsible for tegumentary leishmaniasis in Brazil.
    Coser EM; Ferreira BA; Yamashiro-Kanashiro EH; Lindoso JAL; Coelho AC
    Acta Trop; 2021 Mar; 215():105806. PubMed ID: 33385363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug combinations for visceral leishmaniasis.
    Olliaro PL
    Curr Opin Infect Dis; 2010 Dec; 23(6):595-602. PubMed ID: 20871400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.